<DOC>
	<DOCNO>NCT01310049</DOCNO>
	<brief_summary>The purpose first-in-man trial determine safety tolerability ascend single multiple dos LEO 32731 healthy male subject . The trial perform three part . In Part 1 , single dos LEO 32731 administer healthy male subject . In Part 2 , effect food single oral dose pharmacokinetic investigate . In Part 3 , multiple dos LEO 32731 administer healthy male subject .</brief_summary>
	<brief_title>LEO 32731 - A Study Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Subjects , prior study related activity , give write informed consent participate study abide study restriction . 2 . Subjects Caucasian male 18 55 year age body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive . 3 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia NOT acceptable ) . 1 . Subjects , whose partner willing use appropriate contraception ( condom ) spermicidal foam/gel/film/cream/suppository time first dose 3 month final dosing occasion . Male subject whose partner childbearing potential must also agree use additional highly effective method contraception 2 . Subjects receive prescribed systemic topical medication within 14 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . 3 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . 4 . Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . 5 . Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) , market drug within past 3 month prior first dose occasion . 6 . Subjects donate blood , plasma platelet 3 month prior screen make donation two occasion within 12 month precede first dose administration . 7 . Subjects significant history drug allergy determine Investigator . 8 . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . 9 . Subjects supine blood pressure supine pulse rate screen high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 50 bpm , respectively 10 . Subjects consume 28 unit alcohol per week significant history alcoholism drug/chemical abuse determine Investigator ( one unit alcohol equal Â½ pint [ 285 mL ] beer lager , one glass [ 125 mL ] wine , 1/6 gill [ 25 mL ] spirit ) . 11 . Subjects positive urine drug screen alcohol breath test result screen first admission . 12 . Subjects smoke smoke 3 month prior first dose administration . 13 . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological , dermatological major disorder determine Investigator . 14 . Subjects clinically significant illness within 4 week start dose administration determine Investigator . 15 . Subjects know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV antibody . 16 . Subjects confirm active/latent tuberculosis ( TB ) . 17 . Subjects , opinion General Practitioner ( GP ) Investigator , participate study , include subject suspect whatever reason able comply requirement protocol . 18 . Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study ; QTcB interval &gt; 450 msec , 2nd 3rd degree Atrioventricular block , complete leave bundle branch block , complete right bundle branch block WolffParkinsonWhite Syndrome define PR &lt; 110 msec , confirm repeat ECG . 19 . Subjects previously take part withdrawn study . 20 . Subjects , opinion Investigator , participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Exploratory study healthy subject</keyword>
</DOC>